ACR Annual Meeting: Gout patients who are admitted to the hospital with worsening heart failure, go on to have gout attacks during hospitalization leading to longer hospital stays, researchers reported November 10 at the annual meeting of the American College of Rheumatology in Atlanta.
Failure to achieve a target serum urate level of below 6 mg/dL among patients with gout is an independent predictor of total and cardiovascular-related mortality, say researchers writing in RMD Open: Rheumatic & Musculoskeletal Diseases this month.
In a study presented at the Clinical Congress of Rheumatology West held in San Diego last month, researchers led by Brian LaMoreaux, M.D., report that gout was found to be a “a common comorbidity in renal transplant patients.”
Aryeh M. Abeles, M.D., talks with Rheumatology Network about the FDA's black box label for febuxostat, a gout treatment which, according to the results of one clinical trial, was shown to be associated with an increased risk of mortality. In this Q&A, Dr. Abeles, says the decision was based on flawed data.
Patients diagnosed with gout at age 40 or younger may be at increased risk for cardiovascular disease and recurrent gout compared to those diagnosed later in life, according to a new study published in ACR Open Rheumatology.
Researchers writing in Arthritis & Rheumatology have found evidence suggesting that osteoarthritis may be a precursor to the development of gout.
While gout does not increase the risk of death post-acute coronary syndrome, a new study suggests it may increase an individual’s risk for readmission after heart failure, as well as the number of days he or she will spend on the hospital.
While gout does not increase the risk of death post-acute coronary syndrome, a new study shows the condition does increase an individual’s risk for readmission after heart failure, as well as the number of days he or she will spend on the hospital.
An intensive treatment strategy that combines ebuxostat (Uloric, Takeda) and the novel verinurad, significantly reduced hyperuricemia and albuminuria in patients with type 2 diabetes patients.
EULAR 2019 wraps this weekend in Madrid. In this slideshow, we highlight some of the most noteworthy findings, beginning with a possible new treatment combination for patients who have both gout and kidney disease.